Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP By Ogkologos - September 22, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Updated results after additional follow-up in the CUPISCO study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate... December 11, 2025 Why I Choose to Live With Gratitude During Metastatic Breast Cancer December 29, 2022 Cancer Does Not Affect All People Equally: An Expert Q&A on... June 30, 2020 Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... May 8, 2021 Load more HOT NEWS Long-Term Responders with No Evidence of Disease Have Better Survival to... Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated... Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane... Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients...
